MDA-MB-231 Orthotopic Mouse Model Service for Breast Cancer

The MDA-MB-231 orthotopic mouse model recapitulates an aggressive, mesenchymal-like triple-negative breast cancer within its native mammary tissue architecture, enabling robust preclinical interrogation of tumor invasion, spontaneous metastasis, and therapeutic response in an immunodeficient host setting. Alfa Cytology delivers precision-engineered MDA-MB-231 orthotopic programs spanning authenticated cell sourcing, surgical implantation into the mammary fat pad, longitudinal tumor and metastasis monitoring, and comprehensive molecular endpoint analysis to advance your TNBC drug discovery pipeline.

Overview of MDA-MB-231 Orthotopic Mouse Model for Breast Cancer

MDA-MB-231 is a human breast cancer cell line originally isolated at the University of Texas MD Anderson Cancer Center from a pleural effusion specimen of a 51-year-old Caucasian female diagnosed with invasive ductal carcinoma. Genomically, the line clusters within the Basal B (mesenchymal-like) molecular subclass of triple-negative breast cancer, exhibiting a spindle-shaped, fibroblastoid morphology with robust vimentin expression and absent E-cadherin—features indicative of an epithelial-to-mesenchymal transition phenotype. The cells carry a missense mutation in TP53, a KRAS activating mutation, and wild-type BRCA1 and PI3K pathway status, rendering them unresponsive to endocrine or anti-HER2 interventions but highly susceptible to agents targeting mesenchymal plasticity, invasion, and metastatic dissemination.

Fig 1. Luciferase-labelling enables the detection of CTCs, multiorgan metastasis and tumour self-seeding in an MDA-MB-231 orthotopic breast cancer model. (Murad, Muhammad, et al., 2024)

When implanted orthotopically into the mammary fat pad of immunodeficient hosts such as nude (Nu/Nu) or NSG mice, MDA-MB-231 tumors establish rapidly and exhibit pronounced local invasiveness coupled with spontaneous metastasis to regional lymph nodes, lung, liver, and bone. The model's exceptional metastatic propensity has been leveraged to generate organotropic subclones—including bone-seeking MDA-231BO (1833) and brain-seeking MDA-231BR variants—through serial in vivo selection. These properties make the MDA-MB-231 orthotopic platform indispensable for studying late-stage breast cancer biology, evaluating anti-metastatic agents, and modeling the metastatic cascade from primary tumor seeding to distal organ colonization.

Cell Line Information: MDA-MB-231

MDA-MB-231 displays a distinctive spindle-shaped, fibroblastoid morphology consistent with its Basal B (mesenchymal-like) classification. Under three-dimensional culture conditions, the line forms stellate, star-like invasive structures rather than the compact spheroids seen in epithelial Basal A lines, reflecting its inherent migratory and invasive capacity. The line is among the most extensively characterized and widely utilized TNBC models in preclinical oncology.

Our Services

Alfa Cytology provides end-to-end MDA-MB-231 orthotopic model services grounded in rigorous preclinical standards, encompassing authenticated ATCC cell line procurement, standardized mammary fat pad surgical implantation, twice-weekly caliper-based tumor volumetrics, metastasis surveillance, and terminal necropsy with histopathological, immunohistochemical, and molecular endpoint analysis to support your TNBC therapeutic pipeline from early candidate screening through anti-metastatic mechanism interrogation.

Workflow of MDA-MB-231 Orthotopic Mouse Model Construction

MDA-MB-231 orthotopic model construction follows a streamlined protocol optimized for the line's rapid proliferation and invasive phenotype. Each stage is executed under controlled surgical and husbandry conditions to ensure high tumor take rates, reproducible growth kinetics, and consistent metastatic behavior.

1. Cell Authentication and Expansion: Low-passage MDA-MB-231 cells are expanded from authenticated ATCC stocks, verified by STR profiling, and confirmed for Basal B marker expression (vimentin-positive, E-cadherin-negative) prior to inoculum preparation.
2. Host Selection and Acclimatization: Female immunodeficient mice (Nu/Nu or NSG, 6–8 weeks) are quarantined for one week, health-screened, and randomized by body weight to establish comparable baseline cohorts.
3. Single-Cell Suspension Preparation: Adherent MDA-MB-231 cells are gently detached with trypsin-EDTA, resuspended in serum-free medium, counted, and diluted to the target concentration; viability is confirmed by trypan blue exclusion exceeding 95%.
4. Orthotopic Surgical Implantation: Under isoflurane anesthesia, a small incision is made over the fourth inguinal mammary gland, the fat pad is exteriorized, and a 50–100 µL cell suspension (1–5 × 10⁶ cells) is injected directly into the mammary adipose tissue using a 27-gauge needle.
5. Wound Closure and Postoperative Care: The incision is closed with sterile wound clips or sutures; postoperative analgesia is administered, and mice are monitored on a warming pad until fully ambulatory.
6. Longitudinal Tumor and Metastasis Monitoring: Tumor dimensions are measured twice weekly with digital calipers (V = 0.5 × L × W²); body weight and clinical signs are recorded concurrently to assess overall health and detect early signs of metastatic burden.
7. Study Randomization and Treatment: Upon reaching a predetermined tumor volume (typically 100–200 mm³), mice are randomized into treatment and vehicle-control groups stratified by tumor size to ensure balanced baseline comparisons.
8. Endpoint Harvest and Multimodal Analysis: At study termination, primary tumors are excised and weighed; draining lymph nodes, lungs, liver, and long bones are harvested for metastasis assessment via histology, IHC, or molecular profiling as specified.

Fig 2. MDA-MB-231 Orthotopic Mouse Model construction workflow.

Case Study-MDA-MB-231 Orthotopic Mouse Model Development

In a preclinical pharmacology program, the MDA-MB-231 orthotopic model was employed to evaluate the anti-metastatic efficacy of a novel therapeutic candidate targeting mesenchymal plasticity and invasion in triple-negative breast cancer. The study monitored primary mammary tumor growth kinetics, spontaneous lymph node and pulmonary metastatic burden, and terminal tissue histopathology, generating quantitative metrics including tumor growth inhibition indices and metastasis suppression ratios to inform downstream candidate prioritization for advanced TNBC indications.

Why Choose Alfa Cytology?

Alfa Cytology brings deep expertise in MDA-MB-231 orthotopic modeling, combining surgical precision with comprehensive metastasis-focused analytical capabilities to deliver actionable preclinical data for your TNBC therapeutic programs.

• Basal B Metastasis Expertise: Specialized proficiency in mesenchymal-like, highly invasive TNBC systems with proven protocols for monitoring spontaneous metastasis to lymph nodes, lung, liver, and bone.
• Organotropic Subclone Access: Capability to leverage bone-seeking (MDA-231BO) and brain-seeking (MDA-231BR) derivatives for site-specific metastasis studies and organotropic therapeutic evaluation.
• Standardized Surgical Protocols: Refined mammary fat pad implantation techniques optimized for MDA-MB-231's rapid growth and invasive phenotype, ensuring high engraftment consistency and reproducible metastatic kinetics.
• Integrated Metastasis Endpoint Portfolio: Comprehensive histopathology, multiplex IHC for EMT markers (vimentin, E-cadherin, Snail, Slug), lymph node and visceral metastasis quantification, and molecular profiling of distal lesions.
• Anti-Invasion and Anti-Metastatic Study Design: Proven capability to evaluate agents targeting EMT, cell motility, matrix metalloproteinases, and the metastatic cascade in a physiologically relevant orthotopic context.

Contact Us

Whether you are advancing a novel anti-metastatic agent, an EMT-targeted therapeutic, or a combination strategy for aggressive triple-negative breast cancer, Alfa Cytology has the technical infrastructure and scientific depth to advance your program. Contact us today to discuss your MDA-MB-231 orthotopic study design, and our team will craft a tailored preclinical program aligned with your discovery milestones and metastasis research objectives.

For research use only. Not intended for any clinical use.